Cost-effectiveness of prescription recommendations for cholesterol-lowering drugs: survey of representative sample of american cardiologists

Objectives. We sought to determine the cost-effectiveness of the recommendations of cardiologists for the pharmacologic treatment of hypercholesterolemia. Background. Despite the publication of guidelines such as the report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, little is known about the national prescribing practices of physicians and how they compare with the recommendations of cost-effectiveness analyses. Methods. Under the auspices of the Cardiovascular Norms Committee of the American College of Cardiology, nationally representative sample of cardiologists was surveyed, and their recommendations for the pharmacologic treatment of hypercholesterolemi were assessed to determine cost-effectiveness. Results. The 346 responding cardiologists were reasonably representative of the membership of the American College of Cardiology. For the 12 hypothetical patients, the cardiologists recommended pharmacologic treatment more commonly in cases in which previously published studies estimated the treatment to be more cost-effective, although there was tendency to recommend such treatment for primary prevention even when it was estimated to cost well over $100,000/year of life saved. Conclusions. These findings suggest that the cardiologistsʹ pharmacologic recommendations for lowering lipids are correlated with published cost-effectiveness analyses. However, substantial variation in their recommendations remains, with somewhat less aggressive treatment for secondary prevention and more aggressive treatment for primary prevention than would be recommended on the basis of cost-effectiveness analyses.